{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-084938","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.454302+00:00","generated_at":"2026-06-08T07:18:13.615226+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Jasper Therapeutics reports Q3 2023 net loss of $17.5M; highlights IND clearance for briquilimab in CSU","bullets":["Net loss of $17.5M ($0.16 per share); R&D expenses $14.8M; G&A expenses $4.5M.","Cash and cash equivalents of $103.9M as of Sept 30, 2023.","FDA cleared IND for Phase 1b/2a study of subcutaneous briquilimab in CSU; first patient expected by end of 2023.","Stanford-sponsored Phase 1/2 study in Fanconi Anemia: all 3 patients achieved full donor engraftment.","Appointed Thomas Wiggans as Chairperson and Herb Cross as CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-084938","json":"https://secwatch.observer/filing/0001213900-23-084938.json","markdown":"https://secwatch.observer/filing/0001213900-23-084938.md","text":"https://secwatch.observer/filing/0001213900-23-084938.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023084938/0001213900-23-084938-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023084938/ea187963-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:18:13.615226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}